Skip to main content
Equibles

APTOF · Aptose Biosciences Inc. · Investor Relations

Track APTOF — free

Use APTOF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research APTOF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.69 +0.00 (+0.00%) At close · Jul 3
Rebalance outlook locked
Going-concern doubt — flagged May 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The aforementioned conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed May 13, 2026
Market Cap
$4.31M
Shares
2.55M
Volume · Jul 3 426 Avg daily vol (2 sessions) 531

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-06-15 TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Event
2026-06-14 European Hematology Association Congress (EHA 2026) Event
2026-03-31 Special Meeting of Shareholders Shareholder meeting
2025-12-06 TUSCANY Study Demonstrates Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Ineligible for Induction Chemotherapy Event
2025-10-16 ESH 2025 Poster - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Event
2025-08-21 TUS Triplet TUSCANY Trial Update - August 2025 Event
2025-06-12 EHA 2025 - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Event
2025-05-05 Aptose Corporate Presentation - Bloom Burton Conference Conference
2025-03-11 Aptose Corporate Presentation March 2025 Presentation
2025-01-13 Aptose Corporate Presentation January 2025 Presentation
2024-12-09 Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML Event
2024-11-07 Aptose Corporate Presentation November 2024 Presentation

Source: https://www.aptose.com/investors

Key facts CIK 882361 CUSIP 03835T408 Visit website Investor relations